¹⁹F (Perfluoropropane) MRI

NCT07305532 | Not Yet Recruiting

• 1 other identifier: SJHCF0001
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.

Conditions

Healthy Volunteers - Male and Female

Keywords

19F(perfluoropropane) MRI

Outcome Measures

Primary Outcomes (4)

• Image spatial resolution

  The primary endpoints are to assess the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high spatial resolution lung images from MRI. Image spatial resolution (mm) is the ability of the imaging system to distinguish small structures, expressed as the smallest detectable detail in millimeters. Higher spatial resolution (smaller values) allows finer anatomical detail to be visualized.

  5 years

• Signal-to-noise ratio (SNR)

  A quantitative measure of image quality that compares the level of the desired signal to the background noise in an MRI image. Higher SNR values indicate clearer images with less noise, allowing for better visualization of anatomical structures.

  5 years

• Contrast-to-noise ratio (CNR)

  A measure of how well different tissues or structures can be distinguished from each other in an image relative to background noise. Higher CNR indicates better contrast and improved visibility of anatomical differences.

  5 years

• Scan duration (minutes)

  The total time required to complete the imaging acquisition for the protocol, measured in minutes.

  5 years

Secondary Outcomes (2)

• Ventilation Defect Percent (VDP) of the lung

  5 years

• Fractional Ventilation (r)

  5 years

Study Arms (1)

¹⁹F (perfluoropropane) MRI

EXPERIMENTAL

Participants will undergo pulmonary function tests, ¹⁹F (perfluoropropane) MRI at the visit.

Device: 19F(perfluoropropane) MRI

Interventions

19F(perfluoropropane) MRI DEVICE

19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.

¹⁹F (perfluoropropane) MRI

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.
• Provision of written, informed consent prior to any study specific procedures.
• Males and females aged 18 to 85 years.
• Participant must be able to perform a breath-hold for 16s.
• Participant has a BMI between 18 and 40
• Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)
• Participants are judged to be in stable health on the basis of medical history

You may not qualify if:

• Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
• In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
• Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
• Participant is unable to perform spirometry maneuvers.
• Participant is unable to perform MRI and CT breath-hold maneuvers.
• Participant has a history of chronic or acute respiratory disease
• FEV1 \<70%
• Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)
• Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine

Sponsors & Collaborators

• Alexei Ouriadov: lead
• St. Joseph's Health Care London: collaborator

Study Sites (1)

St Joseph's Healthcare London

London, Ontario, N6A 4V2, Canada

Location

Central Study Contacts

Hana Serajeddini, MD, FRCPC

CONTACT

(519) 646-6100; hana.serajeddini@lhsc.on.ca

Tommy Li, Msc

CONTACT

zli3569@uwo.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PhD, professor, scientist

Model Details: Device: ¹⁹F (perfluoropropane) MRI

Study Record Dates

• First Submitted: December 12, 2025
• First Posted: December 26, 2025
• Study Start (Estimated): May 20, 2026
• Primary Completion (Estimated): August 30, 2030
• Study Completion (Estimated): December 30, 2030
• Last Updated: April 22, 2026

Record last verified: 2025-12

Locations

CA (1)